U.S., Jan. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07355062) titled 'A Study to Evaluate the Efficacy and Safety of Veverimer for the Treatment of Metabolic Acidosis' on Nov. 25, 2025.
Brief Summary: The purpose of this 26 week study is is to evaluate the efficacy and safety of veverimer in treating adults with moderate-to-severe chronic kidney disease (CKD) and metabolic acidosis.
Study Start Date: Jan. 15
Study Type: INTERVENTIONAL
Condition:
CKD
Metabolic Acidosis
Intervention:
DRUG: Veverimer
Group 1: 9 g veverimer BID
DRUG: Placebo
Group 2: 9 g PBO BID
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Renibus Therapeutics, Inc.
Published by HT Digital Content Services with permission f...